These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30712431)

  • 1. Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.
    Luo N; Lippmann SJ; Mentz RJ; Greiner MA; Hammill BG; Hardy NC; Laskey WK; Heidenreich PA; Chang CL; Hernandez AF; Curtis LH; Peterson PN; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2019 Feb; 8(3):e010484. PubMed ID: 30712431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
    Luo N; Fonarow GC; Lippmann SJ; Mi X; Heidenreich PA; Yancy CW; Greiner MA; Hammill BG; Hardy NC; Turner SJ; Laskey WK; Curtis LH; Hernandez AF; Mentz RJ; O'Brien EC
    JACC Heart Fail; 2017 Apr; 5(4):305-309. PubMed ID: 28359417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Insurance Status and Region on Angiotensin Receptor-Neprilysin Inhibitor Prescription During Heart Failure Hospitalizations.
    Davogustto G; Wells QS; Harrell FE; Greene SJ; Roden DM; Stevenson LW
    JACC Heart Fail; 2024 May; 12(5):864-875. PubMed ID: 38639698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin Receptor-Neprilysin Inhibitor Is Associated With Improved Cardiac Autonomic Function in Heart Failure.
    Boehmer AA; Schubert T; Rothe M; Keim C; Wiedenmann L; Ruckes C; von Stuelpnagel L; Theurl F; Schreinlechner M; Dobre BC; Kaess BM; Bauer A; Ehrlich JR
    J Am Heart Assoc; 2024 Aug; 13(15):e033538. PubMed ID: 39082399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical guidance on the use of sacubitril/valsartan for heart failure.
    Sauer AJ; Cole R; Jensen BC; Pal J; Sharma N; Yehya A; Vader J
    Heart Fail Rev; 2019 Mar; 24(2):167-176. PubMed ID: 30565021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
    DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis.
    Rattanavipanon W; Sotananusak T; Yamaae F; Chandrsawang A; Kaewkan P; Nathisuwan S; Yingchoncharoen T
    BMC Cardiovasc Disord; 2021 Jul; 21(1):324. PubMed ID: 34215190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
    Vaduganathan M; Desai AS
    Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
    Wang Y; Zhou R; Lu C; Chen Q; Xu T; Li D
    J Am Heart Assoc; 2019 Jul; 8(13):e012272. PubMed ID: 31240976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter Study.
    Hsu CY; Chung FP; Chao CJ; Chen YJ; Wu CK; Wu YW; Huang JL; Chu PH; Jia-Yin Hou C; Chang HY; Hung CL
    Mayo Clin Proc; 2024 Jun; 99(6):940-952. PubMed ID: 38530689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
    Ekici B; Yaman M; Küçük M; Dereli S; Yenerçağ M; Yiğit Z; Baş MM; Karavelioğlu Y; Çakmak HA; Kıvrak T; Özkan H; Altın C; Şabanoğlu C; Demirkan B; Ataş AE; Kılıçaslan F; Altay H; Tengiz İ; Fahri Erkan A; Kılıçaslan B; Olgun FE; Durakoğlugil ME; Alhan A; Zoghi M
    Turk Kardiyol Dern Ars; 2021 Jul; 49(5):357-367. PubMed ID: 34308869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Initiative Increasing GDMT Use Among Patients With Heart Failure With Reduced Ejection Fraction.
    Minciunescu A; Rosner C; Kepplinger D; Del Castillo T; Overbeck D; Levy WS; O'Connor CM; Haddad TM
    JACC Heart Fail; 2024 Aug; 12(8):1487-1493. PubMed ID: 38934962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
    DeVore AD; Hill CL; Thomas L; Sharma PP; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Hernandez AF; Fonarow GC
    Circ Heart Fail; 2018 Sep; 11(9):e005400. PubMed ID: 30354360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.